Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
14M
-
Shares change
-
-214K
-
Total reported value, excl. options
-
$45.9M
-
Value change
-
-$780K
-
Number of buys
-
6
-
Number of sells
-
-5
-
Price
-
$3.29
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q1 2020
19 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2020.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14M shares
of 122M outstanding shares and own 11.49% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (6.32M shares), NEA Management Company, LLC (4.44M shares), Omega Fund Management, LLC (1.26M shares), FMR LLC (793K shares), FRANKLIN RESOURCES INC (587K shares), VANGUARD GROUP INC (150K shares), DRIEHAUS CAPITAL MANAGEMENT LLC (117K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (75K shares), BANCO BILBAO VIZCAYA ARGENTARIA, S.A. (70K shares), and Schonfeld Strategic Advisors LLC (59K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.